Press Releases
![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-1-300x127.png)
More Volunteers from Traditionally Underrepresented Communities Needed in Alzheimer’s Clinical Trials
Global Alzheimer’s Platform Foundation to present information about trial diversity at the Alzheimer’s Association International Conference. WASHINGTON, DC, July 27, 2022 — As a leading organization focused on increasing participant diversity in Alzheimer’s clinical trials, the Global Alzheimer’s Platform Foundation® (GAP) will present data at the Alzheimer’s Association International Conference® 2022 (AAIC®) to share information about its […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2022/07/IMG_3792-300x225.jpeg)
GAP Takes Alzheimer’s Clinical Trials On the Road to Remove Barriers to Access
Global Alzheimer’s Platform Foundation’s new mobile research site is taking Alzheimer’s clinical trials on the road to traditionally underrepresented communities. WASHINGTON, DC, July 14, 2022 — Today, Global Alzheimer’s Platform Foundation (GAP) announced the launch of a new mobile health site, which is hitting the road to reduce barriers to clinical trial participation. While more than six […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2022/05/gns_logo-02-2.png)
GNS and the Global Alzheimer’s Platform Foundation® Partner to Advance Alzheimer’s R&D
3-year partnership will leverage biomarker database and AI for innovation to create“Digital Twins” that help uncover the complex biology driving Alzheimer’s Disease Somerville, Mass., June 1st, 2022 — GNS, the leader in the use of “Virtual Patients,” Causal AI and simulation technology for biopharmaceutical drug discovery and development, and the Global Alzheimer’s Platform Foundation® (GAP) today […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/09/John-Dwyer.jpg)
STATEMENT: THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® PRESIDENT JOHN DWYER CONDEMNS THE CMS DECISION TO LIMIT A CLASS OF ALZHEIMER’S DRUGS AS “RATIONING CARE”
Washington, D.C. (April 7, 2022) – “Today, the Centers for Medicare and Medicaid Services (CMS) issued its final coverage ruling for an entire class of Alzheimer’s drugs. At its core, this National Coverage Decision (NCD) is not very different here from a flat-out denial of coverage. CMS continues to treat all Alzheimer’s patients differently than any other class […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-1-300x127.png)
Biden Administration and Congress Take a Major Step to Accelerate Research to Treat and Cure Serious Illnesses
Modeled after DARPA, ARPA-H will incentivize innovative approaches to address some of America’s deadliest diseases Washington, D.C. (March 30, 2022) – A group of leading scientists and patient advocates today applauded the Biden Administration and Congress for making the Advanced Research Projects Agency for Health (ARPA-H) a reality. This new agency is designed to empower […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-300x127.png)
THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® ECHOES CONCERNS RAISED BY SENATORS WARNER AND MARKEY AND COLLEAGUES
CMS FAILS TO FAIRLY EVALUATE ALZHEIMER’S TREATMENTS Washington, D.C. (March 23, 2022) — Adding to the growing number of advocates calling on the U.S. Centers for Medicare and Medicaid Services (CMS) to reconsider an unprecedented National Coverage Determination (NCD) that discriminates against 6 million people with Alzheimer’s disease, U.S. Senators Mark R. Warner (D-VA) and […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-1-300x127.png)
STATEMENT BY JOHN DWYER, PRESIDENT OF THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® ON PRESIDENT BIDEN’S STATE OF THE UNION ADDRESS
Washington, D.C. (March 1, 2022) – “He did it again. From his victory speech in November 2020 and then again in his initial address to the nation in 2021, and then tonight in his most major address yet unveiling his ‘Unity Agenda,’ President Biden put Alzheimer’s disease near the top of the U.S. national public […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2022/02/GAPAwards2022-300x169.png)
Four Alzheimer’s Clinical Trial Volunteers Honored with National Citizen Scientist Awards® for Their Work in Search of a Cure
Global Alzheimer’s Platform Foundation® Honorees Include the First Canadian Recipient, Advocate to Veterans, Caregiver, and First Honoree with Parkinson’s Disease Contact: Andi Zucchi – andizucchi@rational360.com, 360-927-8767 Washington, DC (February 23, 2022) – The Global Alzheimer’s Platform Foundation (GAP) is honoring four clinical trial volunteers with 2021 National Citizen Scientist Awards. This year’s recipients include the […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2022/02/MedVadis_Logo-Crop-removebg-300x46.png)
MedVadis Research Joins GAP-Net in Fight to Accelerate Alzheimer’s Treatment
MedVadis Research will join the Global Alzheimer’s Platform Foundation® Network (GAP-Net) of more than 100 global clinical trial sites Washington, D.C. (February 10, 2022) – The Global Alzheimer’s Platform Foundation® (GAP) announced that MedVadis Research has joined its network of more than 100 global clinical trial sites (GAP-Net), a team of leading academic and private […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-1-300x127.png)
“Punitive, restrictive and unprecedented”: Global Alzheimer’s Platform Foundation President® John Dwyer Comments on CMS Draft National Coverage Determination
Dwyer calls on Centers for Medicare & Medicaid Services to provide coverage for the entire class of mAb drugs approved by the Food & Drug Administration and future drugs yet to be approved Washington, D.C. (February 11, 2022) – The Centers for Medicare & Medicaid Services (CMS) proposed plan to limit coverage of an entire […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2022/02/NCDCEDTimeline2_2Feb22-300x210.png)
Clinicians and Researchers Urge CMS to Reform Decision to Limit Coverage of Alzheimer’s Treatments
Experts voice concerns over pre-judging promising treatments in the pipeline Today, five top Alzheimer’s clinicians and researchers called into question the preliminary proposal from the Centers for Medicare and Medicaid Services (CMS) to limit coverage FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease. The CMS proposal would alter the course of […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2022/02/NCDCEDTimeline2_2Feb22-300x210.png)
Global Alzheimer’s Platform Foundation® Applauds Neurologists for Speaking Out Against Proposed CMS Plan to Restrict Coverage to Alzheimer’s Patients
New survey finds that 83% of neurologists believe that the safety and efficacy of an entire class of drugs should not be determined by the results of one medication. Washington, D.C. (February 2, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/09/John-Dwyer.jpg)
STATEMENT: Global Alzheimer’s Platform Foundation® Applauds Biogen for 18 Percent Diversity Recruitment Goal for Participants in Aduhelm Confirmatory Trial
Washington, D.C. (January 27, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, applauded the announcement today by Biogen Inc. that it would ensure that at least 18 percent of participants in its FDA mandated study will […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-1-300x127.png)
Global Alzheimer’s Platform Foundation® (GAP) Condemns CMS Preliminary Coverage Decision on First Disease Modifying Drug for Alzheimer’s as Repudiation of President’s Promise to Advance Treatments for Alzheimer’s for all Americans
GAP calls for a traditional National Coverage Determination for ADUHELM consistent with past CMS decisions which will ensure access and equity for all patients stricken with Alzheimer’s. Washington, D.C. (January 11, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-1-300x127.png)
Global Alzheimer’s Platform Foundation® Applauds Biogen for Reducing Cost of ADUHELM
GAP Renews Its Call for CMS to Cover the New Class of Drugs for the Treatment of Alzheimer’s Washington, D.C. (December 20, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-1-300x127.png)
Atlanta Metro Communities Gain Access to Renowned Alzheimer’s Research Network Through Local Clinical Trial Site
iResearch Atlanta will join the Global Alzheimer’s Platform Foundation®’s network (GAP-Net) of clinical trial sites working to bring new treatments to those living with the disease and and improve equity in research. Contact: Peter Buonanno – peterbuonanno@rational360.com – 704.989.5501 WASHINGTON, D.C. (December 7, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) announced that iResearch Atlanta […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/151022_GAPF_Full_Logo_Color-1-300x127.png)
Orlando Seniors Gain Access to Innovative Alzheimer’s Clinical Trial
Study leaders at new Global Alzheimer’s Network Site Commit to Improving Equity in Florida Alzheimer’s Research Contact: Peter Buonanno – peterbuonanno@rational360.com – 408-466-5952 Washington, DC (November 18, 2021) – With enrollment in full swing, the Global Alzheimer’s Platform Foundation® (GAP) has announced that K2 Medical Research will join both their GAP-Network of clinical trial sites […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/11/lynnehughes-300x300.jpeg)
Global Alzheimer’s Platform Foundation (GAP) Taps Leading International Clinical Trial Expert for Senior Advisor Role
Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/10/AXIOM-1-300x89.png)
To Beat Alzheimer’s, Tampa Seniors From Underserved Communities can get Involved in Clinical Trials
GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/07/Screen-Shot-2021-07-28-at-9.38.53-AM-300x62.png)
Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) to Partner with the Global Alzheimer’s Platform Foundation® (GAP) and Other Industry Leaders on Breakthrough Alzheimer’s Study
Contact: Peter Buonanno – peterbuonanno@rational360.com, 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2020/06/151022_GAPF_Full_Logo_Color-300x127.jpg)
Statement: Global Alzheimer’s Platform Foundation Praises FDA for Aducanumab Approval
Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/01/biohermes-1-300x268.png)
Bio-Hermes Clinical Trial Launches to Compare Biomarker Tests; Seeks Rapid, Less Expensive Diagnostics for Alzheimer’s Disease
Lilly, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation, and leading technology companies join the first platform study assessing various biomarker tests’ ability to predict the presence of Alzheimer’s Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2021/04/INWRlogo.png)
Inland Northwest Research Screens First Patient Worldwide for Study of Investigational Parkinson’s Disease Drug
GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson’s disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) […]
Read more »![](https://globalalzplatform.org/wp-content/uploads/2019/11/John-Dwyer-246x300.jpg)
Statement to the FDA on Support for Aducanumab for Treatment of Early Stage AD
GAP President John Dwyer wrote to the FDA in support of the Aducanumab drug developed by Biogen. Dear Dr. Woodcock, On behalf of the Global Alzheimer’s Platform Foundation (GAP) and millions of Alzheimer’s patients and caregivers across the nation, I urge the Food and Drug Administration (FDA) to approve aducanumab for treatment of early stage […]
Read more »